Helen Torley sold $153k of HALO
PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 1,923 shares at an average of $79.77, traded Jul 8, 2026, filed Jul 9, 2026.
Score components
- +25RoleCEO
- +11Trade size$153k at market
- 0Share of holdings soldSold 0.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001159036-26-000100, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | MOption exercise Common Stock10b5-1 | +1,923 | $12.07 | $23k | 769,703 | Jul 9, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock10b5-1 | -888 | $79.28 | $70k | 768,815 | Jul 9, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock10b5-1 | -1,035 | $80.19 | $83k | 767,780 | Jul 9, 2026 |
| Jul 8, 2026 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -1,923 | $12.07 | $23k | 0 | Jul 9, 2026 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.3M 60,000 shares | -8% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $167k 1,626 shares | -4% | |
| 20Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $125k 1,625 shares | -4% | |
| 24Weak | HALOZYME THERAPEUTICS, INC. | Mahesh Krishnan director | $548k 7,304 shares | -34% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.4M 50,000 shares | -6% | |
| 13Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $108k 1,625 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.